Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD

36.85  +1.76 (+5.02%)

After market: 36.84 -0.01 (-0.03%)

Fundamental Rating

7

EXEL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. EXEL has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EXEL is not overvalued while it is showing excellent growth. This is an interesting combination. This makes EXEL very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

EXEL had positive earnings in the past year.
In the past year EXEL had a positive cash flow from operations.
Each year in the past 5 years EXEL has been profitable.
EXEL had a positive operating cash flow in each of the past 5 years.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

EXEL's Return On Assets of 17.68% is amongst the best of the industry. EXEL outperforms 98.22% of its industry peers.
Looking at the Return On Equity, with a value of 23.23%, EXEL belongs to the top of the industry, outperforming 97.87% of the companies in the same industry.
EXEL has a better Return On Invested Capital (21.31%) than 98.58% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for EXEL is below the industry average of 14.04%.
The 3 year average ROIC (10.78%) for EXEL is below the current ROIC(21.31%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 17.68%
ROE 23.23%
ROIC 21.31%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

With an excellent Profit Margin value of 24.04%, EXEL belongs to the best of the industry, outperforming 97.51% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
EXEL's Operating Margin of 31.81% is amongst the best of the industry. EXEL outperforms 98.58% of its industry peers.
In the last couple of years the Operating Margin of EXEL has declined.
With an excellent Gross Margin value of 96.49%, EXEL belongs to the best of the industry, outperforming 96.98% of the companies in the same industry.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 31.81%
PM (TTM) 24.04%
GM 96.49%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so EXEL is creating value.
Compared to 1 year ago, EXEL has less shares outstanding
Compared to 5 years ago, EXEL has less shares outstanding
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 10.27 indicates that EXEL is not in any danger for bankruptcy at the moment.
EXEL has a better Altman-Z score (10.27) than 87.39% of its industry peers.
EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.27
ROIC/WACC2.24
WACC9.52%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

EXEL has a Current Ratio of 3.63. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL's Current ratio of 3.63 is in line compared to the rest of the industry. EXEL outperforms 42.81% of its industry peers.
A Quick Ratio of 3.58 indicates that EXEL has no problem at all paying its short term obligations.
EXEL has a Quick ratio (3.58) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.58
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 189.06% over the past year.
Measured over the past years, EXEL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.65% on average per year.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.50%.
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)189.06%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%77.78%
Revenue 1Y (TTM)18.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%18.16%

3.2 Future

The Earnings Per Share is expected to grow by 25.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 9.91% on average over the next years. This is quite good.
EPS Next Y12.27%
EPS Next 2Y14.46%
EPS Next 3Y19.76%
EPS Next 5Y25.81%
Revenue Next Year3.53%
Revenue Next 2Y6.83%
Revenue Next 3Y8.96%
Revenue Next 5Y9.91%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 19.92, which indicates a rather expensive current valuation of EXEL.
Based on the Price/Earnings ratio, EXEL is valued cheaply inside the industry as 95.91% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 29.63, EXEL is valued a bit cheaper.
EXEL is valuated rather expensively with a Price/Forward Earnings ratio of 17.74.
EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.38% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of EXEL to the average of the S&P500 Index (22.68), we can say EXEL is valued slightly cheaper.
Industry RankSector Rank
PE 19.92
Fwd PE 17.74
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EXEL indicates a rather cheap valuation: EXEL is cheaper than 97.16% of the companies listed in the same industry.
97.16% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 15.36
EV/EBITDA 10.87
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
EXEL has an outstanding profitability rating, which may justify a higher PE ratio.
EXEL's earnings are expected to grow with 19.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.62
PEG (5Y)1.58
EPS Next 2Y14.46%
EPS Next 3Y19.76%

More info and screens

0

5. Dividend

5.1 Amount

EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (2/21/2025, 8:16:29 PM)

After market: 36.84 -0.01 (-0.03%)

36.85

+1.76 (+5.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)04-28 2025-04-28/amc
Inst Owners87.56%
Inst Owner Change1.77%
Ins Owners1.67%
Ins Owner Change2.05%
Market Cap10.31B
Analysts75.86
Price Target37.74 (2.42%)
Short Float %4.77%
Short Ratio5.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.01%
Min EPS beat(2)10.66%
Max EPS beat(2)13.37%
EPS beat(4)3
Avg EPS beat(4)38.82%
Min EPS beat(4)-17.73%
Max EPS beat(4)148.98%
EPS beat(8)5
Avg EPS beat(8)14.06%
EPS beat(12)9
Avg EPS beat(12)18.4%
EPS beat(16)11
Avg EPS beat(16)52.58%
Revenue beat(2)1
Avg Revenue beat(2)3.28%
Min Revenue beat(2)-1.38%
Max Revenue beat(2)7.95%
Revenue beat(4)2
Avg Revenue beat(4)7.85%
Min Revenue beat(4)-9.49%
Max Revenue beat(4)34.34%
Revenue beat(8)3
Avg Revenue beat(8)3.15%
Revenue beat(12)5
Avg Revenue beat(12)1.98%
Revenue beat(16)7
Avg Revenue beat(16)4.23%
PT rev (1m)8.8%
PT rev (3m)20.65%
EPS NQ rev (1m)8.01%
EPS NQ rev (3m)9.52%
EPS NY rev (1m)1.67%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-0.01%
Revenue NY rev (1m)0.14%
Revenue NY rev (3m)0.14%
Valuation
Industry RankSector Rank
PE 19.92
Fwd PE 17.74
P/S 4.76
P/FCF 15.36
P/OCF 14.73
P/B 4.6
P/tB 4.73
EV/EBITDA 10.87
EPS(TTM)1.85
EY5.02%
EPS(NY)2.08
Fwd EY5.64%
FCF(TTM)2.4
FCFY6.51%
OCF(TTM)2.5
OCFY6.79%
SpS7.75
BVpS8.02
TBVpS7.79
PEG (NY)1.62
PEG (5Y)1.58
Profitability
Industry RankSector Rank
ROA 17.68%
ROE 23.23%
ROCE 27.12%
ROIC 21.31%
ROICexc 37.84%
ROICexgc 39.6%
OM 31.81%
PM (TTM) 24.04%
GM 96.49%
FCFM 30.96%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score9
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 98.72%
Cap/Sales 1.31%
Interest Coverage 250
Cash Conversion 97.39%
Profit Quality 128.83%
Current Ratio 3.63
Quick Ratio 3.58
Altman-Z 10.27
F-Score9
WACC9.52%
ROIC/WACC2.24
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)189.06%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%77.78%
EPS Next Y12.27%
EPS Next 2Y14.46%
EPS Next 3Y19.76%
EPS Next 5Y25.81%
Revenue 1Y (TTM)18.5%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%18.16%
Revenue Next Year3.53%
Revenue Next 2Y6.83%
Revenue Next 3Y8.96%
Revenue Next 5Y9.91%
EBIT growth 1Y303.74%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year26.49%
EBIT Next 3Y0.06%
EBIT Next 5Y1.16%
FCF growth 1Y129.31%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y110%
OCF growth 3Y20.43%
OCF growth 5Y5.84%